Boston Scientific to acquire Symetis for $435 million

Boston Scientific Corporation announced a definitive agreement to acquire Symetis SA, a Swiss structural heart company, for $435 million in up-front cash. The acquisition expands Boston Scientific's TAVI portfolio and is expected to close in Q2 2017.

“Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash.”news.bostonscientific.com

• 4 sources
• news.bostonscientific.comBoston Scientific Announces Agreement to Acquire SymetisMar 30, 2017
• sec.govBOSTON SCIENTIFIC CORP Form 8-K filed March 30, 2017Mar 30, 2017
• reuters.comSymetis, Boston Scientific reach $435 mln purchase agreementMar 30, 2017
• medicaldevice-network.comBoston Scientific to purchase Symetis for $435m - Medical Device NetworkApr 2, 2017

Summarized from public sources; check the original articles before acting on it.